Buy KLOW: The Regeneration Blend for Researchers

Peptide research has evolved in recent years from studying individual peptides to exploring synergistic combinations. KLOW is one such combination - a proprietary blend of four peptides, each well-documented in regeneration research: BPC-157, TB-500, GHK-Cu and KPV. Together, they address different phases of tissue repair and complement each other across multiple signalling pathways.

KLOWregeneration

4-in-1 anti-aging peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg. Targets collagen synthesis, tissue regeneration, skin repair, and anti-inflammatory pathways.

For researchers looking to source KLOW in research-grade quality, the key questions are: What exactly does it contain, why this particular combination, and what should you look for when purchasing?

What Is KLOW?

KLOW is a multi-peptide blend with a total content of 80 mg, combining four bioactive peptides in a single vial:

BPC-157 (Body Protection Compound-157): A pentadecapeptide consisting of 15 amino acids, derived from a protective protein in human gastric juice. Its effects on tendon, muscle and tissue repair have been documented in hundreds of preclinical studies.
TB-500 (Thymosin Beta-4 Fragment): A 43-amino acid peptide involved in actin regulation, studied in research for its role in cell migration, angiogenesis and systemic regeneration.
GHK-Cu (Glycyl-L-histidyl-L-lysine-Copper): A copper tripeptide that occurs naturally in human plasma and declines with age. GHK-Cu has been shown to stimulate collagen synthesis and modulate gene expression related to tissue repair.
KPV (Lys-Pro-Val): An anti-inflammatory tripeptide derived from alpha-MSH (alpha-melanocyte-stimulating hormone). Studies by Dalmasso et al. (2008, Gastroenterology) demonstrated that KPV is taken up via the PepT1 transporter and significantly reduces intestinal inflammation.

Why Is This Combination Being Researched?

The rationale behind KLOW is based on the understanding that tissue repair is not a single process but a cascade of inflammation control, cell migration, angiogenesis and matrix remodelling. Each component addresses different phases:

Phase 1 - Inflammation Control: KPV inhibits NF-kB-mediated inflammatory signalling. Studies show that KPV has even stronger anti-inflammatory effects than the complete alpha-MSH molecule (Luger et al., 2003, Annals of the New York Academy of Sciences). Simultaneously, BPC-157 modulates the JAK-2/STAT-3 signalling pathway and reduces pro-inflammatory cytokines.

Phase 2 - Cell Migration and Angiogenesis: TB-500 promotes cell migration through actin sequestration and supports the formation of new blood vessels. BPC-157 upregulates VEGF and EGF, promoting neovascularisation in damaged tissue.

Phase 3 - Matrix Remodelling: GHK-Cu stimulates the synthesis of collagen, elastin and glycosaminoglycans. A comprehensive review by Pickart et al. (2018, Cosmetics) documents GHK-Cu's ability to influence the expression of over 4,000 genes, including many associated with tissue repair and anti-ageing.

Overview of Mechanisms of Action

The four peptides in KLOW act through complementary signalling pathways:

NO Modulation: BPC-157 influences the nitric oxide system, thereby promoting blood flow to the repair site.
NF-kB Inhibition: KPV suppresses nuclear translocation of NF-kB, a key regulator of the inflammatory response.
Actin Regulation: TB-500 binds to G-actin, promoting cell motility and tissue reorganisation.
Copper-Mediated Gene Expression: GHK-Cu activates genes involved in wound healing via copper-dependent signalling pathways.

This multi-pathway activity is why the combination is considered potentially synergistic in research - the individual peptides complement each other rather than simply acting additively.

Quality Criteria When Buying KLOW

For a multi-peptide blend like KLOW, quality control is even more important than for individual peptides. Researchers should look for the following:

Independent Analytics: Every batch should be tested by an independent laboratory. At PeptidesDirect, KLOW is verified by Janoshik Analytical - one of the most recognised laboratories worldwide for peptide analytics. The Certificate of Analysis (COA) should include HPLC purity analyses for all four components, mass spectrometry for identity confirmation, and data on peptide content and residual moisture.

Purity: Research-grade quality requires a purity of at least 98% for each individual component. Impurities in multi-blends can lead to unwanted interactions and compromise research results.

Correct Ratios: The dosage of individual peptides within the 80 mg blend must be precise so that synergistic effects can be studied reproducibly.

Dosages in Research Literature

Since KLOW is a proprietary blend, no specific dosage studies exist for the exact combination. However, dosages for the individual components are well documented:

BPC-157: Animal models typically use 10 µg/kg body weight (Sikiric et al., various studies). Common research protocols work with dosages between 200-500 µg subcutaneously.
TB-500: Research protocols frequently use 2-5 mg as an initial dose, followed by maintenance doses of 1-2 mg.
GHK-Cu: Topical studies have used concentrations of 1-10 µg/ml. Systemic dosages vary in the literature.
KPV: Dalmasso et al. used oral administration in their colitis models, while subcutaneous research protocols work with 100-500 µg.

The dosage of the KLOW blend depends on the specific research protocol and questions being investigated.

Storage and Handling

KLOW is supplied as a lyophilised powder and is stable in this form when stored correctly:

Before reconstitution: Store at -20 °C. The lyophilised powder remains stable under these conditions for months.
After reconstitution: Store in the refrigerator at 2-8 °C and use within 2-4 weeks.
Reconstitution: Perform with bacteriostatic water. Allow the water to run slowly down the inside wall of the vial - do not spray directly onto the powder. Gently swirl, do not shake.
Light protection: KLOW is light-sensitive. Use dark vials or store protected from light.

Why Buy KLOW from PeptidesDirect?

For researchers in the EU, PeptidesDirect offers several advantages:

Janoshik-verified: Every batch is independently tested by Janoshik Analytical and certificates of analysis are available.
EU shipping: Shipped from within the EU - no customs, no import fees, no risk of border seizure.
Fast delivery: 2-3 business days with tracking within the EU.
Research-grade quality: At least 98% purity for all peptide components.

KLOW 80 mg is available at PeptidesDirect for €154.99.

Frequently Asked Questions

What is KLOW used for? KLOW is intended exclusively for in-vitro and preclinical research. It is not an approved medicine and is not intended for human consumption.

What distinguishes KLOW from individual peptides? The multi-blend addresses different phases of tissue repair simultaneously - inflammation control (KPV), local healing (BPC-157), systemic regeneration (TB-500) and matrix remodelling (GHK-Cu). This makes the combination interesting for researchers investigating synergistic effects.

How should I store KLOW correctly? As lyophilised powder at -20 °C. After reconstitution with bacteriostatic water, store in the refrigerator at 2-8 °C and use within four weeks. Store protected from light.

What analytics are available? Every batch is independently tested by Janoshik Analytical. The COA includes HPLC purity analyses, mass spectrometry and peptide content for all four components.

Are there human studies on KLOW? No human studies exist for the specific combination. For the individual components - particularly BPC-157 and GHK-Cu - there is extensive preclinical data and initial clinical investigations.

KLOWregeneration

4-in-1 anti-aging peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg. Targets collagen synthesis, tissue regeneration, skin repair, and anti-inflammatory pathways.